The FDA recently approved Inrebic® (Fedretinib) for Myelofibrosis, the first new treatment in decades. Available as a once-daily oral dose, this is a new option for patients. Learn more: https://ir.celgene.com/press-releases/press-release-details/2019/US-FDA-Approves-INREBIC-Fedratinib-as-First-New-Treatment-in-Nearly-a-Decade-for-Patients-With-Myelofibrosis/default.aspx

JOHNS CREEK, Ga. The Pharmacy Anti-Steering and Transparency Act, which will go into effect Jan. 1, 2020, prohibits insurers and benefits managers who have ownership in a pharmacy from steering patients to that business. The law endeavors to reduce conflicts of interests, increase transparency and give patients more choice. The law was inspired in part […]

A recently published Phase III Trial by Athenex, Inc. showed that oral paclitaxel in combination with encequidar was superior to IV paclitaxel for Overall Response Rate in Metastatic Breast Cancer. Patients in the oral combination group also had less incidence of neuropathy than the intravenous group. Learn more at: https://ir.athenex.com/news-releases/news-release-details/athenex-announces-oral-paclitaxel-and-encequidar-had

MISSION STATEMENT / PHILOSOPHY: With experience, commitment and a shared vision of how we can positively impact patients’ lives, we’re changing the future of healthcare in our community. Understanding that each of our patients is a unique individual, our goal is to: provide the most advanced, clinically-proven treatments for their disease; provide access to clinical […]

On July 17th, the governor of Oregon signed a bill into the law; Oregon House Bill 2185 has been passed unanimously, imposing new requirements on Pharmacy Benefit Managers (PBMs) registered in Oregon. Effective January 1st, 2020, PBMs may not require a prescription to be filled or refilled by a mail order pharmacy if a dispensing […]

Although drug rebates have been an area of high focus for reform, the Trump Administration decided yesterday to withdraw its plan to eliminate rebates from government-sponsored drug plans. Read more

Letter to the Committee on Finance – Phair Pricing Act (S.640) The Honorable Chuck Grassley Chairman Committee on Finance 135 Hart Senate Office Building United States Senate Washington, D.C. 20510 The Honorable Ron Wyden Ranking Member Committee on Finance 221 Dirksen Senate Office Building United States Senate Washington, D.C. 20510   Dear Chairman Grassley and […]

Written by: Ann Schwemm, PharmD, MPH, BCOP, University of Minnesota Health Download Here Cyclin-dependent kinase (CDK) 4/6 inhibitors have demonstrated significant advances in the treatment of hormone receptor (HR) positive and human epidermal growth factor receptor (HER2) negative advanced breast cancer. While current available data do not support the preferential use of one agent over […]

Kirollos S. Hanna, PharmD, BCPS, BCOP Oral oncolytics, or oral chemotherapies, have significantly impacted the treatment of cancer. They enable patients to conveniently manage treatment in their homes. Despite the rapid growth, therapeutic advances, novel mechanisms of actions, and improved outcomes associated with these agents, the dispensing process remains inadequate. As a result of rising drug […]

A recent study evaluated chest, head and neck cancer patients receiving radiation and determined that use of statin medications can reduce the risk of stroke by 32% (statistically significant).  The effects of radiation can cause scarring and thickening of the arteries, which can lead to blockages down the line; statins help protect the arteries and […]

MISSION STATEMENT/PHILOPSOPHY: Mission: To deliver cutting-edge, compassionate, integrated urologic care, supported by evidence-based medicine, that optimizes quality of life for our patients while increasing value to all stakeholders. Vision: We will serve as the national leader in integrated urologic healthcare by setting the standard for patient experience, employee satisfaction, and provider excellence. LOCATION(S): 43 total  (https://www.njurology.com/locations/) […]

A recent study found that patients receiving Daratumumab treatment may benefit from an alternative dosing technique of subcutaneous (SQ) administration vs. the traditional IV infusion.  Clinicians should be aware of advancing developments that have the potential to reduce the treatment burden and positively impact a patient’s quality of life. READ MORE HERE